Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.55 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.55 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.55 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.55 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.55 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4858409 | 0.90 | MAPT (0.58) | MEN1KMT2AGRIN2BGRIN2DGRIN3B | |
| SCHEMBL4806180 | 0.90 | GRIN2D (0.68) | MEN1KMT2AGRIN2BGRIN2DGRIN3B | |
| SCHEMBL4858602 | 0.88 | MEN1 (0.59) | MEN1KMT2AGRIN2BGRIN2DGRIN3B | |
| SCHEMBL4809215 | 0.82 | GRIN2B (0.43) | MEN1KMT2AGRIN2B | |
| SCHEMBL4816013 | 0.82 | MEN1 (0.58) | MEN1KMT2AGRIN2BGRIN2DGRIN3B | |
| SCHEMBL4810227 | 0.80 | MEN1 (0.56) | MEN1KMT2AGRIN2BGRIN2DGRIN3B | |
| SCHEMBL4879020 | 0.80 | MEN1 (0.56) | MEN1KMT2AGRIN2BGRIN2DGRIN3B | |
| SCHEMBL4856911 | 0.80 | MEN1 (0.59) | MEN1KMT2AGRIN2BGRIN2DGRIN3B | |
| SCHEMBL4853185 | 0.80 | MEN1 (0.56) | MEN1KMT2AGRIN2BGRIN2DGRIN3B | |
| SCHEMBL4509427 | 0.79 | GRIN2D (0.61) | MEN1KMT2AGRIN2BGRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919355-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2005-07-19 | — | — | US | claimed |
| US-20030199552-A1 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. | 2003-10-23 | — | — | US | claimed |
| US-7378431-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-05-27 | — | — | US | disclosed |
| US-7375116-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-05-20 | — | — | US | disclosed |
| US-7365083-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-04-29 | — | — | US | disclosed |
| US-7361670-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-04-22 | — | — | US | disclosed |
| US-20050159451-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-07-21 | — | — | US | disclosed |
| US-6919355-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2005-07-19 | — | — | US | disclosed |
| US-20050113359-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20050113361-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20050113360-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20030199552-A1 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113361-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | MEN1 2735/4885KMT2A 525/4885GRIN2B 3/4885 |
| US-20050113360-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | MEN1 3002/4885KMT2A 548/4885GRIN2B 3/4885 |
| US-20050159451-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | MEN1 2664/4885KMT2A 514/4885GRIN2B 3/4885 |
| US-20050113359-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | MEN1 2684/4885KMT2A 503/4885GRIN2B 3/4885 |
| US-20030199552-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2C | MEN1 4425/4885KMT2A 760/4885GRIN2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.